COMPARISON of TWO DOSES of INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT for MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION Results of the Pan American Collaborative Retina Study Group at 24 Months

Página do item simplificado
dc.contributor.authorWu, Lihteh
dc.contributor.authorArevalo, J. Fernando
dc.contributor.authorBerrocal, Maria H.
dc.contributor.authorMaia, Mauricio [UNIFESP]
dc.contributor.authorRoca, Jose A.
dc.contributor.authorMorales-Canton, Virgilio
dc.contributor.authorAlezzandrini, Arturo A.
dc.contributor.authorDiaz-Llopis, Manuel J.
dc.contributor.institutionInst Cirugia Ocular
dc.contributor.institutionClin Oftalmol Ctr Caracas
dc.contributor.institutionUniv Puerto Rico
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionClin Ricardo Palma
dc.contributor.institutionHosp Luis Sanchez Bulnes
dc.contributor.institutionUniv Buenos Aires
dc.contributor.institutionInst Oftalmol Valencia
dc.date.accessioned2016-01-24T14:05:09Z
dc.date.available2016-01-24T14:05:09Z
dc.date.issued2010-07-01
dc.description.abstractPurpose: the purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion.Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). the main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months.Results: All patients completed at least 24 months of follow-up. the mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 +/- 6 0.57 units (P < 0.0001) versus 0.27 +/- 0.68 units for the 2.5-mg dose group (P < 0.0001). These differences were not statistically significant between both dose groups. in the 1.25-mg dose group, 25 (56.8%) eyes gained >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. in the 2.5-mg dose group, 24 (57.1 %) eyes improved >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. the CMT in the 1.25-mg dose group improved from 635 +/- 324 mu m to 264 +/- 160 mu m (P < 0.0001) versus 528 +/- mu m to 293 +/- 137 mu m in the 2.5-mg dose group (P < 0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction.Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity. RETINA 30:1002-1011, 2010en
dc.description.affiliationInst Cirugia Ocular, San Jose, Costa Rica
dc.description.affiliationClin Oftalmol Ctr Caracas, Retina & Vitreous Serv, Caracas, Venezuela
dc.description.affiliationUniv Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA
dc.description.affiliationUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.affiliationClin Ricardo Palma, Lima, Peru
dc.description.affiliationHosp Luis Sanchez Bulnes, Asociac Para Evitar La Ceguera, Mexico City, DF, Mexico
dc.description.affiliationUniv Buenos Aires, Inst Oftalm Alta Complejidad, Buenos Aires, DF, Argentina
dc.description.affiliationInst Oftalmol Valencia, Valencia, Spain
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent1002-1011
dc.identifierhttp://dx.doi.org/10.1097/IAE.0b013e3181cea68d
dc.identifier.citationRetina-the Journal of Retinal and Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 30, n. 7, p. 1002-1011, 2010.
dc.identifier.doi10.1097/IAE.0b013e3181cea68d
dc.identifier.issn0275-004X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/32695
dc.identifier.wosWOS:000279635600002
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofRetina-the Journal of Retinal and Vitreous Diseases
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectbevacizumaben
dc.subjectintravitreal injectionen
dc.subjectmacular edemaen
dc.subjectretinal vein occlusionen
dc.subjectVEGFen
dc.titleCOMPARISON of TWO DOSES of INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT for MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION Results of the Pan American Collaborative Retina Study Group at 24 Monthsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral